Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

NCT07342517 is registered in ClinicalTrials.gov with Relmada Therapeutics, Inc. as lead sponsor.

NCT NCT07342517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07342517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
Lead sponsor
Relmada Therapeutics, Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
June 30, 2026
Completion date
June 30, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder (urothelial, transitional cell) cancer, bladder (urothelial, transitional cell) cancer superficial (non-invasive), urologic cancer, urothelial carcinoma bladder, urothelial carcinoma recurrent